As co-host of the IPO Bootcamp, held on Tuesday, October 9, at the Union Club in Boston, LHS was thrilled to be the investor relations consultant for executives looking for best practices for a successful IPO. The day began with an opening address from David Ethridge of PwC on the current state of the IPO market, and continued with an overview of the healthcare ECM from Jordan Saxe, Senior Managing Director at Nasdaq. A roundtable discussion on determining and defining an IPO strategy followed, with leaders from PwC, Nasdaq, Covington & Burling, Oppenheimer & Co, and LavoieHealthScience offering insights.
We are also grateful to have had SVP and General Manager, Doug Russell, moderate the LSX panel on Big Data Driven Innovation on Thursday, October 11. Pharma and life science executives discussed how they’re harnessing the power of big data to advance drug discovery and development. Panelists included Leila Pirhaji, Founder and CEO of ReviveMed, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, Gini Desphande, Founder and CEO of NuMedii, Alex de Winter, Managing Director at GE Ventures, and Janna Hutz, Senior Director, Head of Human Biology & Data Science at Eisai. Doug led a lively discussion on the topic, with a focus on the future promise of big data in life science innovation.
CEO Donna LaVoie and Paul Sagan, AVP, Investor Relations and Communications, also conducted fireside chats with pharma executives at the LSX World Congress. Pavan Cheruvu, the CEO of Axovant, spoke with Donna LaVoie on the details of building a successful gene therapy portfolio. Later in the evening, Paul Sagan and Brian Pereira, the CEO of Visterra, discussed the anatomy of a clinical-stage acquisition. Pereira, whose company was recently acquired by the Pharmaceutical Co., Ltd of Japan, offered a timely and relevant perspective on the topic.
The two day conference offered many interesting and engaging panels as well as great networking opportunities. LHS is happy to have partnered with LSX this year for a successful World Congress.